BR112022014701A2 - Formulação de injeção intratumoral quimioterápica básica - Google Patents

Formulação de injeção intratumoral quimioterápica básica

Info

Publication number
BR112022014701A2
BR112022014701A2 BR112022014701A BR112022014701A BR112022014701A2 BR 112022014701 A2 BR112022014701 A2 BR 112022014701A2 BR 112022014701 A BR112022014701 A BR 112022014701A BR 112022014701 A BR112022014701 A BR 112022014701A BR 112022014701 A2 BR112022014701 A2 BR 112022014701A2
Authority
BR
Brazil
Prior art keywords
formulation
base
basic
intratumoral
injectable
Prior art date
Application number
BR112022014701A
Other languages
English (en)
Inventor
Sang Pui Hing
Shu Pui Yip
Ching Pui Yip
Original Assignee
US Nano Food & Drug INC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Nano Food & Drug INC filed Critical US Nano Food & Drug INC
Publication of BR112022014701A2 publication Critical patent/BR112022014701A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

FORMULAÇÃO DE INJEÇÃO INTRATUMORAL QUIMIOTERÁPICA BÁSICA. A presente invenção refere-se a uma formulação injetável intratumoral, um método para fabricar a formulação injetável intratumoral e um método para tratar uma massa maligna em um mamífero por administração da formulação injetável diretamente na massa maligna. A formulação intratumoral injetável pode ser uma emulsão, solução ou suspensão, todas compreendendo uma quantidade terapeuticamente eficaz de um fármaco quimioterápico básico dissolvido ou suspenso em um veículo biocompatível, em que o fármaco quimioterápico básico é uma base de antraciclina, uma base de alcaloide de vina, uma base de eribulina ou uma base de agente alquilante.
BR112022014701A 2020-04-13 2021-03-30 Formulação de injeção intratumoral quimioterápica básica BR112022014701A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009220P 2020-04-13 2020-04-13
PCT/US2021/025006 WO2021211294A1 (en) 2020-04-13 2021-03-30 Basic chemotherapeutic intratumour injection formulation

Publications (1)

Publication Number Publication Date
BR112022014701A2 true BR112022014701A2 (pt) 2022-10-25

Family

ID=78007204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014701A BR112022014701A2 (pt) 2020-04-13 2021-03-30 Formulação de injeção intratumoral quimioterápica básica

Country Status (13)

Country Link
US (1) US11752165B2 (pt)
EP (1) EP4135686A1 (pt)
JP (1) JP2023520975A (pt)
KR (1) KR20220167271A (pt)
CN (1) CN114929213A (pt)
AR (1) AR121835A1 (pt)
AU (1) AU2021257738A1 (pt)
BR (1) BR112022014701A2 (pt)
CA (1) CA3169441A1 (pt)
IL (1) IL297015A (pt)
MX (1) MX2022010387A (pt)
TW (1) TW202203938A (pt)
WO (1) WO2021211294A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115802961A (zh) * 2020-05-18 2023-03-14 开米美景公司 使用分子化学成像检测口腔癌的系统和方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
JP2880292B2 (ja) 1992-11-27 1999-04-05 ナプロ バイオセラピューティクス，インコーポレイテッド 注射可能組成物
ATE220894T1 (de) * 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5681846A (en) 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
JP4634694B2 (ja) 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US20040241094A1 (en) 2001-09-13 2004-12-02 Hesson Chung Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
CN1840193B (zh) * 2005-03-29 2010-05-12 中国科学院生物物理研究所 聚乙二醇化磷脂包载的蒽环类抗肿瘤抗生素的纳米胶束制剂
CA2611592A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
CN1923189A (zh) 2005-08-30 2007-03-07 孔庆忠 一种紫杉碱类抗癌药物的缓释注射剂
CN100594902C (zh) * 2005-09-09 2010-03-24 梁伟 聚乙二醇衍生化磷脂包载的长春花生物碱类抗肿瘤药物的纳米胶束制剂
CN101322681B (zh) * 2007-06-13 2011-01-19 中国科学院生物物理研究所 一种制备蒽环类抗肿瘤抗生素的纳米胶束制剂的方法
NZ581589A (en) 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
RU2518240C2 (ru) 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
CA2749151A1 (en) 2009-01-16 2010-07-22 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102048725B (zh) 2009-10-29 2014-07-16 中国医学科学院药物研究所 紫杉醇胆固醇复合物
CN102370645B (zh) 2010-08-04 2014-07-23 山东新时代药业有限公司 一种抗癌药物组合物
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
JP5868414B2 (ja) 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド タキソイドの医薬組成物
CN102294015A (zh) * 2011-09-16 2011-12-28 重庆寰瑞生物技术有限公司 一种用于肿瘤靶向治疗的药物组合物及其制备方法
AU2013318338B2 (en) 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
CN104257605A (zh) * 2014-09-04 2015-01-07 山东新时代药业有限公司 一种盐酸表柔比星注射液及其制备方法
CN109475492B (zh) 2016-04-04 2022-04-29 克里蒂泰克公司 实体肿瘤治疗方法
SG11201808913WA (en) 2016-04-15 2018-11-29 Dynavax Tech Corp Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
KR20200032092A (ko) 2017-07-17 2020-03-25 인스티튜트 구스타브 루시 주사용 유중수 에멀젼 및 이의 용도
WO2020035806A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
CN114796111A (zh) * 2021-01-28 2022-07-29 北京德立福瑞医药科技有限公司 一种含有难溶性药物的浓缩液以及由其制备的乳剂
CN113577029B (zh) * 2021-07-14 2023-04-11 中国药科大学 具有改良溶出性质和表观溶解度的药物组合物及其制备方法

Also Published As

Publication number Publication date
MX2022010387A (es) 2022-09-05
CN114929213A (zh) 2022-08-19
AU2021257738A1 (en) 2022-05-19
EP4135686A1 (en) 2023-02-22
TW202203938A (zh) 2022-02-01
KR20220167271A (ko) 2022-12-20
WO2021211294A1 (en) 2021-10-21
US11752165B2 (en) 2023-09-12
IL297015A (en) 2022-12-01
US20210315913A1 (en) 2021-10-14
JP2023520975A (ja) 2023-05-23
AR121835A1 (es) 2022-07-13
CA3169441A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BR112018076639A2 (pt) quimioterapias de combinação
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112022022331A2 (pt) Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
BRPI0608766A8 (pt) microsfera substancialmente esférica, composição, e, métodos para administração de medicamento e para embolização ativa em um mamífero
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
BRPI0608840B8 (pt) composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
BR112015022896A2 (pt) drogas de alta penetração e suas composições para o tratamento de doenças de parkinson
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BR112022014701A2 (pt) Formulação de injeção intratumoral quimioterápica básica
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
BR112023015067A2 (pt) Composto de quinazolina para induzir a degradação de proteína kras g12d mutante
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112018000051A2 (pt) formulações para tratar síndrome de hunter e uso desta
BR112015018549A8 (pt) métodos de tratamento de deficiência de ferro
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112023000220A2 (pt) Formulações de longa ação